Revenue growth remains strong at 30% YoY with record account additions, but operating expenses grew 36% and net loss widened. The raised guidance suggests confidence in continued adoption, but the company remains unprofitable. Monitor the trajectory of operating leverage and the contribution from the newly launched delirium product in coming quarters.
Price Chart
Executive Summary
Ceribell reported Q3 2026 revenue of $29.3M (+30% YoY), slightly above the $29.2M consensus, while GAAP EPS of -$0.55 missed the consensus estimate of -$0.52. The company raised its full-year 2026 revenue guidance to $115M-$117M, reflecting continued momentum in its core seizure monitoring business and the full launch of its delirium monitoring solution.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue of $29.3M, up 30% from $22.6M in Q3 2025
- Product revenue $22.2M (+31% YoY), subscription revenue $7.1M (+28% YoY)
- GAAP net loss of $21.4M, or -$0.55 per share, vs -$13.5M (-$0.37) in Q3 2025
- Adjusted EBITDA loss of $12.1M vs -$9.2M in Q3 2025
- Full-year 2026 revenue guidance raised to $115M-$117M (prior $114M-$117M), representing ~29%-31% YoY growth
- 747 total active accounts at quarter end, record 35 net new customers added
- Gross margin of 90%, down from 92% in Q2 2026 but up from 88% in Q3 2025
- Cash and marketable securities of $117.5M as of September 30, 2026
Financial Impact
Revenue of $29.3M vs consensus $29.2M; GAAP EPS -$0.55 vs consensus -$0.52; guidance raised to $115M-$117M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product | $22.2M | +30.7% |
| Subscription | $7.1M | +27.6% |
Risk Factors
- Net loss and adjusted EBITDA loss are widening year-over-year as operating expenses outpace revenue growth
- Company is pre-profitability with a history of net losses and limited operating history
- Reliance on third-party manufacturers in China and Vietnam introduces supply chain and geopolitical risk
- Patent infringement litigation against Natus Medical adds legal expense uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-445487 |
| Document: cbll-20261103.htm | 0001193125-26-445487 |
| Document: 0001193125-26-445487-index-headers.html | 0001193125-26-445487 |
| Document: 0001193125-26-445487-index.html | 0001193125-26-445487 |
| Document: 0001193125-26-445487.txt | 0001193125-26-445487 |
| 8-K Data (Synthetic) | 0001193125-26-445487 |
Track record
39 reports on CBLL
7 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +17.06% at T+60 after the Feb 23, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 17, 2026today Insider Cluster Neutral 3/10 Entry $26.09 Now $26.42 +1.26% settles Nov 19
- Nov 16, 20261d ago SC 13G/A Neutral 2/10 Entry $26.42 Now $26.42 +0.00% settles Nov 18
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $26.42 to $25.97 Now $26.42 +0.00% ▼ −1.70% −0.69% vs SPY
- Nov 13, 20264d ago Insider Cluster Neutral 2/10 Entry $26.42 to $25.97 Now $26.42 +0.00% ▼ −1.70% −0.69% vs SPY
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $26.14 to $26.42 Now $26.42 +1.07% ▲ +1.07% +2.98% vs SPY
- Nov 10, 20267d ago Insider Cluster Neutral 2/10 Entry $27.80 to $26.35 Now $26.42 −4.96% ▼ −5.22% −4.86% vs SPY
- Nov 9, 20268d ago 144 Neutral 2/10 Entry $27.60 to $27.48 Now $26.42 −4.28% ▼ −0.43% −0.07% vs SPY
- Nov 3, 202614d ago 8-K Neutral 5/10 Viewing No price data
- Nov 3, 202614d ago Press Release Neutral 5/10 Entry $27.39 to $26.01 Now $26.42 −3.54% ▼ −5.04% −0.63% vs SPY
- Nov 2, 202615d ago 144 Neutral 2/10 Entry $26.96 to $28.27 Now $26.42 −2.00% ▲ +4.86% +4.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers